Ipratropium Bromide

DRUG INFORMATION

  ADULT
    - The usual starting dosage of ATROVENT HFA is two inhalations four times a day.
      Patients may take additional inhalations as required; however, the total number of
      inhalations should not exceed 12 in 24 hours. ATROVENT HFA is a solution aerosol
      that does not require shaking. However, as with any other metered-dose inhaler,
      some coordination is required between actuating the canister and inhaling the
      medication.
      Source: US FDA label for ipratropium bromide (Atrovent HFA), section 'dosage and
      administration', retrieved 2026-08-29

  CHILD
    - Safety and effectiveness in the pediatric population have not been established.
      Source: US FDA label for ipratropium bromide (Atrovent HFA), section 'pediatric
      use', retrieved 2026-08-29

  RENAL IMPAIRMENT
    - No kidney-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for ipratropium bromide (Atrovent
      HFA), retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - No liver-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for ipratropium bromide (Atrovent
      HFA), retrieved 2026-08-29

  PREGNANCY
    - Risk Summary Ipratropium is negligibly absorbed systemically following oral
      inhalation; therefore, maternal use is not expected to result in fetal exposure to
      the drug [ see Clinical Pharmacology (12.3) ].
      Source: US FDA label for ipratropium bromide (Atrovent HFA), section 'pregnancy',
      retrieved 2026-08-29
    - There is limited experience with ipratropium bromide use in pregnant women.
      Source: US FDA label for ipratropium bromide (Atrovent HFA), section 'pregnancy',
      retrieved 2026-08-29
    - Published literature, including cohort studies, case control studies and case
      series, over several decades have not identified a drug associated risk of major
      birth defects, miscarriage or adverse maternal or fetal outcomes.
      Source: US FDA label for ipratropium bromide (Atrovent HFA), section 'pregnancy',
      retrieved 2026-08-29

  BREASTFEEDING
    - This effect is not considered relevant to human use due to the large doses at
      which it was observed and the difference in route of administration. 8.2 Lactation
      Risk Summary There are no data on the presence of ipratropium in either human or
      animal milk, the effects on the breastfed infant, or the effects on milk
      production.
      Source: US FDA label for ipratropium bromide (Atrovent HFA), section 'use in
      specific populations', retrieved 2026-08-29
    - Although lipid-insoluble quaternary cations pass into breast milk, ipratropium
      concentrations in plasma after inhaled therapeutic doses are low, therefore,
      ipratropium levels in human breast milk are expected to be low [ see Clinical
      Pharmacology (12.3) ].
      Source: US FDA label for ipratropium bromide (Atrovent HFA), section 'use in
      specific populations', retrieved 2026-08-29
    - The developmental and health benefits of breastfeeding should be considered along
      with the mother's clinical need for ATROVENT HFA and any potential adverse effects
      on the breastfed child from ATROVENT HFA or from the underlying maternal
      condition. 8.4 Pediatric Use Safety and effectiveness in the pediatric population
      have not been established.
      Source: US FDA label for ipratropium bromide (Atrovent HFA), section 'use in
      specific populations', retrieved 2026-08-29